We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Clarifies Clinical Requirements for Fixed-Dose Combination Drugs
EMA Clarifies Clinical Requirements for Fixed-Dose Combination Drugs
Sponsors seeking EU authorization to market fixed-dose drug combinations should conduct multiarm, randomized, controlled trials comparing the FDC with its individual components, the European Medicines Agency says.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor